BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sekido M, Fujita K, Kubota Y, Ishida H, Takahashi T, Ohkuma R, Tsunoda T, Ishikawa F, Shibanuma M, Sasaki Y. Rabeprazole intake does not affect systemic exposure to capecitabine and its metabolites, 5′-deoxy-5-fluorocytidine, 5′-deoxy-5-fluorouridine, and 5-fluorouracil. Cancer Chemother Pharmacol 2019;83:1127-35. [DOI: 10.1007/s00280-019-03837-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
Number Citing Articles
1 Afzali M, Mostafavi A, Shamspur T. A novel electrochemical sensor based on magnetic core@shell molecularly imprinted nanocomposite (Fe3O4@graphene oxide@MIP) for sensitive and selective determination of anticancer drug capecitabine. Arabian Journal of Chemistry 2020;13:6626-38. [DOI: 10.1016/j.arabjc.2020.06.018] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
2 Menon A, Abraham AG, Mahfouz M, Thachuthara JJ, Usmani N, Warkentin H, Ghosh S, Nijjar T, Severin D, Tankel K, Paulson K, Mulder K, Roa W, Joseph K. Concomitant Use of Proton Pump Inhibitors With Capecitabine Based Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer: Is it Safe? Am J Clin Oncol 2021;44:487-94. [PMID: 34269694 DOI: 10.1097/COC.0000000000000850] [Reference Citation Analysis]
3 Matsumoto N, Kubota Y, Ishida H, Sekido M, Ohkuma R, Ishiguro T, Hirasawa Y, Ariizumi H, Tsunoda T, Ikusue T, Kobayashi K, Hisamatsu A, Toshima H, Shimada K, Fujita KI. Variants of carboxylesterase 1 have no impact on capecitabine pharmacokinetics and toxicity in capecitabine plus oxaliplatin treated-colorectal cancer patients. Cancer Chemother Pharmacol 2020;85:1119-28. [PMID: 32458030 DOI: 10.1007/s00280-020-04087-z] [Reference Citation Analysis]
4 Patel A, Spychalski P, Antoszewska M, Regula J, Kobiela J. Proton pump inhibitors and colorectal cancer: A systematic review. World J Gastroenterol 2021; 27(44): 7716-7733 [PMID: 34908809 DOI: 10.3748/wjg.v27.i44.7716] [Reference Citation Analysis]
5 Inaishi T, Fujita KI, Matsumoto N, Shimokata T, Maeda O, Kikumori T, Hattori N, Nakayama G, Ando Y. Correlation Between the Metabolic Conversion of a Capecitabine Metabolite, 5'-Deoxy-5-fluorocytidine, and Creatinine Clearance. In Vivo 2020;34:3539-44. [PMID: 33144465 DOI: 10.21873/invivo.12196] [Reference Citation Analysis]
6 van Doorn L, Heersche N, de Man FM, de Bruijn P, Bijl I, Oomen-de Hoop E, Eskens FALM, van der Gaast A, Mathijssen RHJ, Bins S. Effect of the Proton Pump Inhibitor Esomeprazole on the Systemic Exposure of Capecitabine: Results of A Randomized Crossover Trial. Clin Pharmacol Ther 2021. [PMID: 34656072 DOI: 10.1002/cpt.2444] [Reference Citation Analysis]